The natural history of histologically proved drug induced liver disease

Gut

Volumn 44, Issue 5, 1999, Pages 731-735

  Aithal, P G ^a   Day, C P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chronic active hepatitis; Diclofenac; Drugs; Toxic hepatitis

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AMOXICILLIN PLUS CLAVULANIC ACID; BUPRENORPHINE; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; COTRIMOXAZOLE; DANTROLENE; DEXTROPROPOXYPHENE; DICLOFENAC; GOLD; HALOTHANE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; OMEPRAZOLE; PHENELZINE; PHENYTOIN; PIROXICAM; PROCAINAMIDE; PROPYLTHIOURACIL; RIFAMPICIN; SULPIRIDE; TETRACYCLINE;

ADULT; AGED; ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033045249     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.5.731     Document Type: Article

References (29)

1. 1 Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, eds. Diseases of the liver. Philadelphia: Lippincott Company, 1993:707-83.
2. 2 Kaplowitz N. Drug metabolism and hepatotoxicity. In: Kaplowitz N, ed. Liver and biliary diseases. Baltimore: Williams and Wilkins, 1992:82-97.
3. 3 Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973;187:211-17.
4. 4 Miller RR. Hospital admissions due to adverse drug reactions: a report from Boston Collaborative Surveillance Program. Arch Intern Med 1974;134:219-23.
5. 5 Lewis JH, Zimmerman HJ, Drug-induced liver disease. Med Clin North Am 1989;73:775-92.
6. 6 Dossing M, Andreasen PB. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 1982;17:205-11.
7. 7 Friis H, Andreasen PB. Drug-induced hepatic injury. An analysis of 1100 cases reported to the Danish committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992;232:133-8.
8. 8 Danan G. Consensus meetings on causality assessment of drug-induced liver injury. J Hepatol 1988;7:132-6.
9. 9 Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology 1977;72:1348-53.
10. 10 Utili R, Boitnott JK, Zimmerman HG. Dantrolene associated hepatic injury. Gastroenterology 1977;72:610-16.
11. 11 Olsson R, Wiholm BE, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15:154-61.
12. 12 Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990;11:272-6.
13. 13 Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-9.
14. 14 Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973;79:1-12.
15. 15 Toghill PJ, Smith PG, Benton P, et al. Methyldopa liver damage. BMJ 1974;3:545-8.
16. 16 Ishak KG, Irey NS. Hepatic injury associated with the phenothiazines. Arch Pathol 1972;93:284-304.
17. 17 Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980;92:14-19.
18. 18 Goldstein GB, Lam KC, Mistills SP. Drug-induced active chronic hepatitis. Am J Dig Dis 1973;18:177-84.
19. 19 Seeff LB. Drug induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis 1981;1:104-15.
20. 20 Cook GC, Sherlock S. Jaundice and its relation to therapeutic agents. Lancet 1965;i:175-9.
21. 21 Almdal TP, Sorensen TIA. Incidence of parenchymal liver diseases in Denmark, 1981-1985: analysis of hospitalisation registry data. Hepatology 1991;13:650-5.
22. 22 Farrell GC. Drug-induced cholestasis. In: Farrell GC, ed. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994:319-70.
23. 23 Banks AT, Zimmerman HJ, Ishak KG, et al. Diclofenacassociated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995;22:820-7.
24. 24 Lindberg J, Lindholm A, Lundin P, et al. Trigger factors and HLA analysis in chronic active hepatitis. BMJ 1975;2:77-9.
25. 25 Farrell GC. Drug-induced chronic active hepatitis. In: Farrell GC, ed. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994:413-30.
26. 26 Newton JL, Burt AD, Park JB, et al. Is the new international diagnostic scoring system for auto-immune disease too rigid [abstract]? Hepatology 1996;24:235A.
27. 27 Iverson TJ, Ryley NG, Kelly PMA, et al. Diclofenac associated hepatitis. J Hepatol 1990;10:85-9.
28. 28 Sallie RW, McKenzie T, Reed WD, et al. Diclofenac hepatitis. Aust N Z J Med 1991;21:251-5.
29. 29 Scully LJ, Clarke D, Barr RJ. Diclofenac-induced hepatitis in 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993;8:744-51.